Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis. What's more, the coverage gap puzzled people who often paid different amounts for ...

The best Medicare plans for cancer patients are a Medigap Plan G from AARP and a Medicare Part D plan from Wellcare. Alternatively, if your cancer diagnosis means you can't qualify for Medigap, choose a Medicare Advantage plan from Aetna. In both cases ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare

An analysis of oncology drugs approved in the United States found that Medicare spending was predominantly driven by the market, not a drug’s therapeutic value.

Like mammograms, breast ultrasounds are covered under Medicare Part B. If you have a Medicare Advantage (Part C) plan instead of Original Medicare (parts A and B), your plan should similarly cover this screening. Some plans may even offer additional benefits that could reduce your costs further.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Women are being forced to consider “flying or dying” as they wait up to four months to get a mammogram following the temporary closure of a critical service in Far North Queensland.

More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four cancer drugs -- palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide (Pomalyst),

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.